Malaysian conglomerate Genting Group’s US$2 million acquisition of a minority stake in Nova Satra DX Pte Ltd


K&L Gates LLP has advised molecular diagnostics and life sciences company Nova Satra DX Pte Ltd (“NSDX”) in relation to a US$2 million investment and acquisition of a minority stake in the company by Malaysian conglomerate Genting Group.

Singapore-based NSDX works in collaboration with global centers of scientific excellence to research, develop and commercialize blood-based tests for cancer. The deal sees Genting Group acquiring an equity stake in NSDX, with the funds raised to be used for working capital, research & development and commercialization purposes.

Singapore partner Nicholas Hanna (picture) led the K&L Gates team on the deal, assisted by Singapore associate Mark Tan.

Involved fees earner: Nicholas Hanna – K&L Gates; Mark Tan – K&L Gates;

Law Firms: K&L Gates;

Clients: Nova Satra DX Pte Ltd;

Print Friendly, PDF & Email
Avatar

Author: Michael Patrini